Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EQL Pharma ABOSTO:EQL -2.66%42 Debt-to-EBITDA is 22.45 as of Mar. 2026, which is 426% above its 10-year median of 4.27. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 689 Drug Manufacturers companies, EQL Pharma AB ranks worse than 91.87% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for EQL Pharma AB's Debt-to-EBITDA or its related term are showing as below:
OSTO:EQL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.55 Med: 4.27 Max: 9.43
Current: 9.43
During the past 13 years, the highest Debt-to-EBITDA Ratio of EQL Pharma AB was 9.43. The lowest was 1.55. And the median was 4.27.
OSTO:EQL's Debt-to-EBITDA is ranked worse than 91.87% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs OSTO:EQL: 9.43
EQL Pharma AB (OSTO:EQL) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
EQL Pharma AB Debt-to-EBITDA Related Terms
EQL Pharma AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
EQL Pharma AB (OSTO:EQL) has a Debt-to-EBITDA of 22.45 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on EQL Pharma AB. This is 426% above median its historical median of 4.27. Over the past decade, EQL Pharma AB's Debt-to-EBITDA has ranged from 1.55 to 9.43. According to the industry distribution chart, EQL Pharma AB ranks #633 out of 689 companies in the Drug Manufacturers industry, placing it in the top 91.9%.
Is EQL Pharma AB's Debt-to-EBITDA too high?
EQL Pharma AB's current Debt-to-EBITDA of 22.45 is 426% above median its 10-year median of 4.27. Over the past 10 years, this metric has ranged from a low of 1.55 to a high of 9.43. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. EQL Pharma AB's value of 22.45 is 1268.9% above this industry median. Based on the distribution chart, EQL Pharma AB ranks #633 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #633 out of 689 companies for Debt-to-EBITDA. This places EQL Pharma AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. EQL Pharma AB's value of 22.45 is 1268.9% above this benchmark. Historically, EQL Pharma AB's own Debt-to-EBITDA has ranged from 1.55 to 9.43 over the past decade. While the company's 10-year median is 4.27 vs. the industry median of 1.64, EQL Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current Debt-to-EBITDA of 22.45 is 1268.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on EQL Pharma AB. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current Debt-to-EBITDA is 22.45, which is 426% above median its own 10-year median of 4.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Debt-to-EBITDA of 22.45. The current Debt-to-EBITDA is 22.45, which is 426% above median its 10-year median of 4.27 and 1268.9% above the Drug Manufacturers industry median of 1.64. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Debt-to-EBITDA is 22.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
